Delving into the Latest Updates on WJ-Pure with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

VL-P22

Target-

Action-

Mechanism-

Therapeutic Areas

Respiratory DiseasesImmune System DiseasesNervous System Diseases+ [3]

Active Indication

Pulmonary Disease, Chronic ObstructiveAlzheimer DiseaseMuscular Dystrophy, Duchenne+ [1]

Inactive Indication

COVID-19COVID-19 respiratory infectionPulmonary Fibrosis+ [1]

Originator Organization

Vitti Labs LLC.

Active Organization

Vitti Labs LLC.

Inactive Organization-

License Organization-

Drug Highest PhaseIND Application

First Approval Date-

Regulation-

Login to view timeline

Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients.
The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. .

Start Date20 Mar 2025

Sponsor / Collaborator

Vitti Labs LLC.

NCT05387239

/ SuspendedPhase 2

Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

The COVID-induced fibrotic lung damage continues long after viral infection has subsided and is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance of developing a persistent respiratory system pathology and a 10% chance of developing a severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration, reduction of exercise tolerance, and concomitant development of persistent fibrotic lung damage. This study intends to evaluate benefits of a combination of VL-P22 and VL-PX10 in Covid-19 patients exhibiting pulmonary fibrosis.

Start Date30 Nov 2022

Sponsor / Collaborator

Vitti Labs LLC.

100 Clinical Results associated with WJ-Pure

Login to view more data

100 Translational Medicine associated with WJ-Pure

Login to view more data

100 Patents (Medical) associated with WJ-Pure

Login to view more data

100 Deals associated with WJ-Pure

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	United States	Vitti Labs LLC.	30 Nov 2022
COVID-19 respiratory infection	Phase 2	United States	Vitti Labs LLC.	30 Nov 2022
Pulmonary Fibrosis	Phase 2	United States	Vitti Labs LLC.	30 Nov 2022
Respiratory Distress Syndrome, Acute	Phase 1	United States	Vitti Labs LLC.	20 Mar 2025
Pulmonary Disease, Chronic Obstructive	IND Application	United States	Vitti Labs LLC.	30 Jan 2022
Alzheimer Disease	Preclinical	United States	Vitti Labs LLC.	30 Jan 2022
Muscular Dystrophy, Duchenne	Preclinical	United States	Vitti Labs LLC.	30 Jan 2022
Osteoarthritis	Preclinical	United States	Vitti Labs LLC.	30 Jan 2022